MedTrace Logo

Tandem Autologous- Nonmyeloablative Allogeneic Transplant for Newly Diagnosed Multiple Myeloma (Trapianto Tandem Autologo-Allogenico Non Mieloablativo Nel Mieloma Alla Diagnosi)

NCT00702247 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2008-06-20

No results posted yet for this study

Summary

To evaluate toxicity profile and efficacy of a tandem autologous-nonmyeloablative transplant approach in newly diagnose myeloma patients younger than 65 years

Conditions

Interventions

PROCEDURE

Hematopoietic Stem Cell Transplantation

Sponsors & Collaborators

  • Azienda Ospedaliera San Giovanni Battista

    lead OTHER

Principal Investigators

  • Bruno Benedetto, MD, PhD · University of Torino - Italy

Study Design

Allocation
NA
Purpose
TREATMENT
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1999-07-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00702247 on ClinicalTrials.gov